Abstract
Twelve prepubertal children with chronic renal failure (CRF) were treated with human growth hormone (GH) (1.2 IU/kg/week) for 2 years. High doses of GH clearly increased growth velocity, from 3.8±1.3 to 9.6±1.5 (P=0.0001) and 6.9 ±0.8 cm/year (P=0.0001) after the 1 st and 2nd year of treatment, respectively, leading to a mean height gain of 1.4 SD. During the 1 st year of treatment the height increment, expressed in SDS, correlated negatively with chronological age (P=0.003). Basal insulin-like growth factor 1 (IGF 1) levels were normal or elevated (7/12 patients) and correlated positively with the overnight integrated GH concentration (r=0.68,P<0.001). Basal insulin-like growth factor binding protein 3 (IGF-BP3) levels were elevated in 8/12 patients. GH induced a significant increase in IGF 1 and IGF-BP3 levels; IGF 1 peaked after 6 months (when growth velocity was optimal) and IGF-BP3 peaked after 12 months. The mean glomerular filtration rate, measured by inulin clearance and corrected for body surface area, fell after the 1st year of treatment, and significantly so at the end of the 2nd year (P=0.02).
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- AUC :
-
area under the curve
- AUCo :
-
area under the curve, estimated above zero level
- AUCb :
-
area under the curve, estimated above the calculated baseline
- CA :
-
chronological age
- CRF :
-
chronic renal failure
- GFR :
-
glomerular filtration rate
- GH :
-
growth hormone
- GHu :
-
urinary growth hormone
- IGFl :
-
insulin-like growth factor 1
- IGF-BP3 :
-
insulin-like growth factor binding protein 3
- SDS :
-
standard deviation score
References
Albertsson-Wikland K, Rosberg S (1988) Analyses of 24 hour growth hormone profile in children: relation to growth, J Clin Endocrinol Metab 67: 493–500
Blum W F, Ranke M B, Kietzmann K, Tönshoff B, Mehls O (1991) Growth hormone resistance and inhibition of somatomedin activity by excess of insulin-like growth factor binding protein in uremia. Pediatr Nephrol 5: 539–544
Fine RN, Kohaut EC, Brown D, Perlman J (1994) Growth after recombinant human growth hormone treatment in children with chronic renal failure: report of a multicenter randomized double-blind placebo-controlled study. J Pediatr 124: 374–382
Fine RN, Yadin O, Moulton L, Nelson PA, Boechat MI, Lippe BM (1994) Five years experience with recombinant human growth hormone treatment of children with chronic renal failure. J Pediatr Endocrinol 7(1): 1–12
Hokken-Koelega ACS, Stijnen T, De Jong MCJW, Donckerwolcke RA, De Miunck Keizer-Schrama SMPF, Blum WF, Drop SLF (1994) Double blind trial comparing the effects of two doses of growth hormone in prepubertal patients with chronic renal insufficiency. J Clin Endocrinol Metab: 1185–1990
Johansson G, Sietnieks A, Janssens F, Proesmans W, Vanderschueren-Lodeweyckx M, Holmberg C, Sipila I, Broyer M, Rappaport R, Albertsson-Wikland K, Berg U, Jodal U, Rees L, Ridgen SPA, Preece MA (1990) Recombinant human growth hormone treatment in short children with chronic renal disease, before transplantation or with functionning renal transplants: an interim report of five European studies. Acta Paediatr Scand 370: S36-S42
Lee PDK, Hintz RL, Sperry JB, Baxter RC, Powell DR (1989) IGF binding proteins in growth-retarded children with chronic renal failure. Pediatr Res 26: 308–315
Leger J, Reverchon C, Porquet D, Noel M, Czenichow P (1995) The wide variation in urinary excretion of urine growth hormone in normal growing and growth hormone deficient children. Horm Res 44: 57–63
Mehls O, Tönshoff B, Haffner D, Wühl E, Schaefer F (1994) The use of recombinant human growth hormone in short children with chronic renal failure. J Pediatr Endocrinol 7(2): 107–113
Merriam GR, Watcher KW (1982) Algorythms for the study of episodic growth hormone secretion. Am J Physiol 243: E310–8
Porquet D, Rigal O, Evain-Brion D, Valade F, Leger J, Czernichow P (1992) Direct double monoclonal immunoradiometric assay of urinary human growth hormone. Clin Chem 39: 1717–1721
Powell DR, Liu F, Baker B, Lee PDK, Craig W, Belsha W, Brewer ED, Hintz RL (1993) Characterization of insulinlike growth factor binding protein-3 in chronic renal failure serum. Pediatr Res 33: 136–143
Rees L, Ridgen S PA, Ward GM (1989) Chronic renal failure and growth. Arch Dis Child 64: 573–577
Rizzoni G, Basso T, Setari M (1984) Growth in children with chronic renal failure on conservative treatment. Kidney Int 26: 52–58
Schwartz GJ (1992) Does kL/PCr estimate GFR, or does GFR determine k? Pediatr Nephrol 6: 451–458
Tönshoff B, Dietz M, Haffner D, Tönshoff C, Stover B, Mehls O (1991) Effects of two years of growth hormone treatment in short children with renal disease. Acta Paediatr Scand 379: S33-S41
Usher RH and MacLean FH (1969) Intra-uterine growth of liveborn caucasian infants at the sea level. J Pediatr 74: 801
Van Diemen-Steenvoorde R, Donckerwolcke RA (1988) Growth and sexual maturation in paediatric patients treated by dialysis and following kidney transplantation. Acta Paediatr Scand [Suppl] 343: 109–116
Van Es on behalf of the European Study Group (1991) Growth hormone treatment in short children with chronic renal failure and after renal transplantation: combined data from european clinical trials. Acta Paediatr Scand [Suppl] 379: 42–48
Van Renen MJ, Hogg RJ, Sweeney AL, Henning PH, Penfold JL, Jureidini KF (1992) Accelerated growth in short children with chronic renal failure treated with both strict dietary therapy and recombinant growth hormone. Pediatr Nephrol 6: 451–458
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Simon, D., Noel, M., Brun, P. et al. Evaluation of clinical and laboratory parameters during 2 years of growth hormone treatment in prepubertal children with chronic renal failure. Eur J Pediatr 155, 688–694 (1996). https://doi.org/10.1007/BF01957154
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01957154